Her viste glykæmiske kontrolmålinger (målt som middelændringer i HbA1c fra baseline), at de var omtrent de samme de to grupper imellem efter et år.
In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA1c was similar between treatment groups after one year.